Genetic testing, including germline and somatic, is vital for prostate cancer prognosis and personalized treatment strategies. PARP inhibitors, targeting BRCA mutations, are a promising therapy for ...

Researchers in Japan have developed a predictive model that could improve treatment decisions for advanced pancreatic cancer patients. By combining tumor marker readings with patients' genetic ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

The NCCN's new resource educates patients on genetic testing for hereditary cancer risk, focusing on breast, ovarian, pancreatic, and prostate cancers. Advances in genetic technology, spurred by the ...

MINNEAPOLIS — By definition, a variant of unknown significance identified in an individual with cardiomyopathy can leave physicians wondering what to do with the information. Don’t discard so-called ...

Results of a program addressing multi-level barriers to completion of hereditary cancer genetic testing (GT) among underserved and minority individuals in Texas. This is an ASCO Meeting Abstract from ...

Black patients and patients from socioeconomically disadvantaged neighborhoods are dramatically under-represented in genetics clinics—often at rates half or less than those of white patients or ...

Cheasanee Huette, a 20-year-old college student in Northern California, is worried. Two years ago, knowing she was protected by the Affordable Care Act's guarantees of coverage for preexisting ...

A genetic testing company has opened a new patient service center in Carlisle. Texas-based Natera Inc. opened the 2,448-square-foot center at 850 Walnut Bottom Road. Natera provides genetic testing in ...

Black patients and patients from socioeconomically disadvantaged neighborhoods are dramatically under-represented in genetics ...